We are live on ! Find out more
QNTM icon

Quantum Biopharma Class B Subordinate Voting Shares

17 hedge funds and large institutions have $895K invested in Quantum Biopharma Class B Subordinate Voting Shares in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

0% more funds holding

Funds holding: 17 → 17 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

2.05% less ownership

Funds ownership: 3.83% → 1.78% (-2%)

74% less capital inflows, than outflows

Capital inflows: $344K | Capital outflows: $1.32M

Holders
17
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

QNTM Hedge Fund Activity: Q3 2025 in Review

17 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q3 2025, worth a combined $895K — down 62% from $2.38M a quarter earlier.

Fund positioning in QNTM was balanced in Q3 2025: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 3 trimmed.

The largest buyer was Marex Group, opening a new position worth an estimated $265K. The largest seller was UBS Group, cutting an estimated $733K.

  • 17 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $895K of Quantum Biopharma Class B Subordinate Voting Shares stock for Q3 2025, down 62% quarter-over-quarter.
  • 4 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q3 2025 and 4 closed out, a net change of 0 holders.
  • The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q3 2025 was Marex Group, an estimated $265K added.
  • The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q3 2025 was UBS Group, an estimated $733K sold.

Based on aggregated 13F filings for Q3 2025.